Investigational drug · Phase 3
DTap-HepB-IPV-Hib vaccine
Also called: Hexyon, Infanrix hexa, Hexyon vaccine
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
9
Any phase or sponsor naming "DTap-HepB-IPV-Hib vaccine"
First trial start
2024
Nov 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DTap-HepB-IPV-Hib vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healthy Volunteers
- Meningococcal Immunization
- Pneumococcal Immunization
- Healthy
- Diarrhoea
Largest trials
Live from ClinicalTrials.gov: studies naming "DTap-HepB-IPV-Hib vaccine" as an intervention, largest first.
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.Pivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT00313911 · 2,133 participants · Start Jul 2006 · Primary completion Jan 2008
Drug: DTaP-IPV-HB-PRP~T; Tritanrix-HepB/Hib · For: Diphtheria; Tetanus; Pertussis and 2 more
Sites: Mexico City, Mexico; Lima, Peru
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05794230 · 1,528 participants · Start Mar 27, 2023 · Primary completion Nov 15, 2025
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine and 13 more · For: Meningococcal Immunisation; Healthy Volunteers
Sites: Chennai, India; Hyderabad, India; Kanpur, India · 15 sites in all
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)Pivotal-lookingCompleted
MCM Vaccines B.V.Industry
NCT01480258 · 1,315 participants · Start Nov 23, 2011 · Primary completion Oct 9, 2013
Drug: PR5I; Rotavirus vaccine and 2 more · For: Bacterial Infections; Virus Diseases
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™Pivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT00654901 · 881 participants · Start Mar 2008 · Primary completion May 2009
Drug: DTaP-IPV-Hep B-PRP~T vaccine (Batch 1); DTaP-IPV-Hep B-PRP~T vaccine (Batch 2) and 2 more · For: Diphtheria; Tetanus; Pertussis and 3 more
Sites: Estado de México, Mexico; Insurgentes Cuicuilco, Mexico; Monterrey, Mexico · 4 sites in all
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsPivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06647407 · 750 participants (planned) · Start Nov 5, 2024 · Primary completion May 17, 2027
Drug: Pentavalent Meningococcal ABCYW vaccine; MenACYW conjugate vaccine and 8 more · For: Meningococcal Immunization; Healthy Volunteers
Sites: Belo Horizonte, Brazil; Curitiba, Brazil; Jindřichův Hradec, Czechia · 39 sites in all
- Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00303316 · 458 participants · Start Feb 2006 · Primary completion Apr 2007
Drug: DTaP-IPV//PRP~T combined vaccine; DTaP-IPV//PRP~T combined vaccine · For: Diphtheria; Tetanus; Pertussis and 2 more
Sites: Córdoba, Argentina
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster VaccinationPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT01839175 · 350 participants · Start Apr 2013 · Primary completion Jul 2014
Drug: Hexavalent vaccine; NeisVac-C and 4 more · For: Neisseria Meningitidis; Bacterial Infections; Virus Diseases
Sites: Espoo, Finland; Helsinki, Finland; Jarvenpaa, Finland · 11 sites in all
- Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgePivotal-lookingStatus unknown
LG ChemIndustry
NCT06618196 · 336 participants (planned) · Start Oct 2, 2024 · Primary completion Jun 30, 2025
Drug: LR20062; DTaP-HepB-IPV-Hib vaccine · For: Diphtheria; Tetanus; Pertussis and 3 more
LG ChemIndustry
NCT05952596 · 42 participants (planned) · Start Jul 17, 2023 · Primary completion Oct 31, 2023
Drug: DTaP-HepB-IPV-Hib vaccine; DTaP-HepB-IPV-Hib vaccine · For: Diphtheria; Tetanus; Pertussis and 3 more
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity of Two Versus Three Doses of Hepatitis B Vaccine When Administered to Children Aged 2-18 Months: A Randomized Clinical Trial.
Kegbevi KB, Febriani Y, Sauvageau C, et al. · J Infect Dis 2026
- Multiparametric analysis of vaccine-induced B and T cell responses for optimal evaluation of memory immune responses to Bordetella pertussis in children.
Smet J, Smits K, Dirix V, et al. · Vaccine 2026
- Bifidobacteria support optimal infant vaccine responses.
Ryan FJ, Clarke M, Lynn MA, et al. · Nature 2025
- Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses.
McAlister SM, van den Biggelaar AHJ, Cooper MN, et al. · Pediatr Infect Dis J 2025
- A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016).
Guerra A, Costantino C, Martinon-Torres F, et al. · Hum Vaccin Immunother 2024
- Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
Pérez Chacón G, Estcourt MJ, Totterdell J, et al. · PLoS Med 2024
Also in development for Healthy Volunteers
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- MenACYW conjugate vaccineNimenrixPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunisation, Meningococcal Immunization
- poliomyelitis vaccinePhase 33 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Whooping Cough, Diphtheria
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
- NVXC19EU licensed, standalonePhase 31 trial
Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.